Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations
- 14 September 2012
- journal article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 36 (2), 179-187
- https://doi.org/10.1007/s10545-012-9533-7
Abstract
Mucopolysaccharidosis (MPS) disorders are heterogeneous and caused by deficient lysosomal degradation of glycosaminoglycans, resulting in distinct but sometimes overlapping phenotypes. Molecular analysis was performed for a total of 355 MPS patients with MPSI (n = 15), MPSII (n = 218), MPSIIIA (n = 86), MPSIIIB (n = 20), MPSIVA (n = 6) or MPSVI (n = 10). This analysis revealed 104 previously unreported mutations: seven in IDUA (MPSI), 61 in IDS (MPSII), 19 in SGSH (MPSIIIA), 11 in NAGLU (MPSIIIB), two in GALNS (MPSIVA) and four in ARSB (MPSVI). The intergenic comparison of the mutation data for these disorders has revealed interesting differences. Whereas IDUA, IDS, NAGLU and ARSB demonstrate similar levels of mutation heterogeneity (0.6–0.675 different mutations per total alleles), SGSH and GALNS have lower levels of mutation heterogeneity (0.282 and 0.455, respectively), due to more recurrent mutations. The type of mutation also varies significantly by gene. SGSH, GALNS and ARSB mutations are usually missense (76.5 %, 81.8 % and 85 %), while IDUA has many more nonsense mutations (56 %) than the other genes (≤20%). The mutation spectrum is most diverse for IDS, including intergenic inversions and multi-exon deletions. By testing 102 mothers of MPSII patients, we determined that 22.5 % of IDS mutations are de novo. We report the allele frequency of common mutations for each gene in our patient cohort and the exonic distribution of coding sequence alterations in the IDS, SGSH and NAGLU genes, which reveals several potential “hot-spots”. This further molecular characterization of these MPS disorders is expected to assist in the diagnosis and counseling of future patients.This publication has 39 references indexed in Scilit:
- Arylsulfatase G inactivation causes loss of heparan sulfate 3- O -sulfatase activity and mucopolysaccharidosis in miceProceedings of the National Academy of Sciences of the United States of America, 2012
- A novel fluorometric enzyme analysis method for Hunter syndrome using dried blood spotsMolecular Genetics and Metabolism, 2012
- A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritisJournal of Inherited Metabolic Disease, 2011
- Tandem Mass Spectrometry for the Direct Assay of Lysosomal Enzymes in Dried Blood Spots: Application to Screening Newborns for Mucopolysaccharidosis II (Hunter Syndrome)Analytical Chemistry, 2010
- Tandem Mass Spectrometry for the Direct Assay of Lysosomal Enzymes in Dried Blood Spots: Application to Screening Newborns for Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome)Analytical Chemistry, 2010
- Determination of urinary oligosaccharides by high-performance liquid chromatography/electrospray ionization–tandem mass spectrometry: Application to Hunter syndromeAnalytical Biochemistry, 2010
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- Effect of ‘attenuated’ mutations in mucopolysaccharidosis IVA on molecular phenotypes of N‐acetylgalactosamine‐6‐sulfate sulfataseJournal of Inherited Metabolic Disease, 2007
- Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutationsHuman Genetics, 2001
- A fluorimetric enzyme assay for the diagnosis of sanfilippo disease type A (MPS IIIA)Journal of Inherited Metabolic Disease, 1995